EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Overcoming the drug resistance barrier: progress in fosfomycin combination therapy against multidrug-resistant pathogens

Yan Wu, Jimin Li, Fengling Qiao, Jinlin Guo, Lin Zhang, Xu Jia

Frontiers in Microbiology · 18.11.2025 · 16

DOI: 10.3389/fmicb.2025.1702881 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Microbiology, online erschienen am 18.11.2025. Verfasst von Yan Wu und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 159 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In the intensifying global crisis of antimicrobial resistance (AMR), the “old” antibiotic fosfomycin has regained prominence because of its unique mechanism of action and potent activity against numerous multidrug-resistant (MDR) pathogens. However, its clinical application is hampered by the rapid emergence of resistance during monotherapy. Rational combination therapy represents a strategic necessity to preserve and enhance the efficacy of fosfomycin. This review systematically analyzes the antibacterial and molecular mechanisms of resistance to fosfomycin, with a focus on the growing threat posed by plasmid-mediated resistance genes. The preclinical and clinical evidence of key combination regimens (including β-lactams, aminoglycosides, fluoroquinolones, polymyxins, and daptomycin) has been comprehensively evaluated, with detailed discussions of the mechanistic foundations for the observed synergistic effects. Although in vitro and animal models show substantial promise, we critically examine the translational gap between positive preclinical results and clinical realities, discussing major barriers to clinical advancement. Finally, we outline a prospective research agenda, encompassing pharmacokinetic/pharmacodynamic (PK/PD)-guided precision dosing, exploring non-antibiotic adjuvants, and developing more predictive preclinical models to unlock the full potential of fosfomycin-based combinations against MDR infections.

Schlagwörter

Stichwörter der Autor:innen

antimicrobial co-administrationantimicrobial resistancecombination therapyfosfomycinmultidrug resistance

Autor:innen und Institutionen

  • College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Chongqing Key Laboratory of Sichuan-Chongqing Co-construction for Diagnosis and Treatment of Infectious Diseases Integrated Traditional Chinese and Western Medicine, Chengdu, China.
  • Key Laboratory of Non-coding RNA and Drug Discovery at Chengdu Medical College, Chengdu, China.
  • Department of Pharmacy, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.
  • School of Basic Medical Sciences, Chengdu Medical College, Chengdu, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wu, Y., Li, J., Qiao, F., Guo, J., Zhang, L., & Jia, X. (2025). Overcoming the drug resistance barrier: progress in fosfomycin combination therapy against multidrug-resistant pathogens. Frontiers in Microbiology, 16. https://doi.org/10.3389/fmicb.2025.1702881

Vancouver

Wu Y, Li J, Qiao F, Guo J, Zhang L, Jia X. Overcoming the drug resistance barrier: progress in fosfomycin combination therapy against multidrug-resistant pathogens. Frontiers in Microbiology. 2025;16. doi:10.3389/fmicb.2025.1702881

BibTeX
@article{Wu2025,
  author = {Wu, Yan and Li, Jimin and Qiao, Fengling and Guo, Jinlin and Zhang, Lin and Jia, Xu},
  title = {Overcoming the drug resistance barrier: progress in fosfomycin combination therapy against multidrug-resistant pathogens},
  journal = {Frontiers in Microbiology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fmicb.2025.1702881}
}
Kostenlos starten →